Resolution on the results of the first working meeting of the Scientific Advisory Board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy»

June 19, 2018 the meeting of the Scientific Advisory Board took place in Moscow, chaired by Professor G.R. Galstyan, (co-chair – A.V. Zilov) devoted to the discussion of the possibilities of improving the results of treatment of diabetes mellitus (DM) by consideration of «variability of glycemia» (VG) as an additional criterion of the glycemic control effectiveness (especially of insulin therapy) as well as one of the goals of treatment in patients with unstable glycemia.

The purpose of the working meeting was to develop a strategy for the introduction of VG as a predictor and an additional criterion in assessing the effectiveness and safety of hypoglycemic therapy to improve the pharmacotherapy of diabetes and reduce cardiovascular and total mortality.

Aims:

– to conduct a comprehensive data analysis of the relationship between VG and adverse DM outcomes, such as hypoglycemia, micro-and macrovascular complications, cardiovascular and total mortality;

– to accumulate and analyze published data and the experience of decrease of VG and improving outcomes of diabetes on the background of different versions of insulin therapy;

– to compare existing methods of glycaemia monitoring and VG assessment, their validity and availability in real practice in the context of limited budget;

– to analyze the informativeness, clinical and prognostic significance of various parameters of VG assessment and determine their reasonable «minimum» for a comprehensive assessment of VG as a criterion for evaluating the effectiveness of treatment of DM and predictors of negative diabetes outcomes.

The following reports were heard during the discussion:

Glycemic variability: clinical and prognostic value. Types of glycemic variability. (Alexey V. Zilov, MD, PhD in Medicine, Assistant Professor).

Methods of assessment of variability of glycemia in clinical trials and routine practice (Tatiana N. Markova, MD, PhD in Medicine, Professor).

Current international and national recommendations on glycemic monitoring (Gagik R. Galstyan, MD, PhD in Medicine, Professor).

Peculiarities of glycemic variability and its evaluation among children and adolescents (Alisa V. Vitebskaya, MD, PhD in Medicine).

glycemia variability, fasting plasma glucose, postprandial glycemia, HbA1c, coefficient of variability, continuous glucose monitoring, self-measured blood glucose, diabetes mellitus

1. Nalysnyk L, Hernandez-Medina М, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288–298. doi: https://doi.org/10.1111/j.1463-1326.2009.01160.x.

2. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37(8):2359–2365. doi: https://doi.org/10.2337/dc14-0199.

3. Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care. 2015;38(8):1610–1614. doi: https://doi.org/10.2337/dc14-2898.

4. Wentholt IM, Kulik W, Michels RP, et al. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51(1):183–190. doi: https://doi.org/10.1007/s00125-007-0842-6.

5. Siegelaar SE, Barwari T, Kulik W, et al. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Tech. 2011;5(1):86–92. doi: https://doi.org/10.1177/193229681100500112.

6. Ohara M, Fukui T, Ouchi M, et al. Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 2016;122:62–70. doi: https://doi.org/10.1016/j.diabres.2016.09.025.

7. Kohnert KD, Augstein P, Zander E, et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care. 2009;32(6):1058–1062. doi: https://doi.org/10.2337/dc08-1956.

8. Kohnert KD, Freyse EJ, Salzsieder E. Glycaemic variability and pancreatic b-cell dysfunction. Curr Diabetes Rev. 2013;8(5):345–354. doi: https://doi.org/10.2174/157339912802083513.

9. Kim MK, Jung HS, Yoon CS, et al. The effect of glucose fluctuation on apoptosis and function of INS-1 pancreatic beta cells. Korean Diabetes J. 2010;34(1):47–54. doi: https://doi.org/10.4093/kdj.2010.34.1.47.

10. Zhang X, Xu X, Jiao X, et al. The effects of glucose fluctuation on the severity of coronary artery disease in type 2 diabetes mellitus. J Diabetes Res. 2013;2013:576916. doi: https://doi.org/10.1155/2013/576916.

11. Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care. 2000;23(1):45–50. doi: https://doi.org/10.2337/diacare.23.1.45.

12. Lin CC, Li CI, Yang SY, et al. Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med. 2012;125(4):416.e9-18. doi: https://doi.org/10.1016/j.amjmed.2011.07.027.

13. Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61(1):48–57. doi: https://doi.org/10.1007/s00125-017-4423-z

14. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med. 2008;36(11):3008–3013. doi: https://doi.org/10.1097/CCM.0b013e31818b38d2

15. DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes. 2013;62(5):1405–1408. doi: https://doi.org/10.2337/db12-1610

16. Климонтов В.В., Мякина Н.Е. Вариабельность гликемии при сахарном диабете: инструмент для оценки качества гликемического контроля и риска осложнений // Сахарный диабет. — 2014. — Т.17. — №2. — С. 76–82. [Klimontov VV, Myakina NE. Glycaemic variability in diabetes: a tool for assessing the quality of glycaemic control and the risk of complications. Diabetes mellitus. 2014;17(2):76–82. (In Russ).]. doi: https://doi.org/10.14341/dm2014276-82

17. Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. 2015;38(8):1615–1621. doi: https://doi.org/10.2337/dc15-0099

18. Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care. 2017;40(7):832–838. doi: https://doi.org/10.2337/dc16-1769

19. Kovatchev BP, Cox DJ, Farhy LS, et al. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab. 2000;85(11):4287–4292. doi: https://doi.org/10.1210/jcem.85.11.6999

20. Patton SR, Clements MA. Average daily risk range as a measure for clinical research and routine care. J Diabetes Sci Technol. 2013;7(5):1370–1375. doi: https://doi.org/10.1177/193229681300700529

21. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955–962. doi: https://doi.org/10.2337/diabetes.53.4.955

22. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability: does it matter. Endocr Rev. 2010;31(2):171–182. doi: https://doi.org/10.1210/er.2009-0021.

23. Qu Y, Jacober SJ, Zhang Q, et al. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther. 2012;14(11):1008–1012. doi: https://doi.org/10.1089/dia.2012.0099

24. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681–1687. doi: https://doi.org/10.1089/dia.2012.0099

25. Seok H, Huh JH, Kim HM, et al. 1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes. Diabetes Metab J. 2015;39(2):164–170. doi: https://doi.org/10.4093/dmj.2015.39.2.164

26. Bailey TS, Bhargava A, DeVries JH, et al. Day-to-day variability of fasting self-measured plasma glucose (SMPG) correlates with risk of hypoglycemia in adults with type 1 (T1D) or type 2 diabetes (T2D). Diabetes. 2017;66(Suppl 1):A104-105(394-P). doi: https://doi.org/10.2337/db17-381-663

27. Bailey TS, Bhargava A, DeVries JH, et al. Within-day variability based on 9-point profiles correlates with risk of overall and nocturnal hypoglycemia in adults with type 1 (t1d) and type 2 diabetes (T2D). Diabetes. 2017;66(Suppl 1):A107(404-P). doi: https://doi.org/10.2337/db17-381-663

28. Vora J, Heise T. Variability of glucose‐lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes Obes Metab. 2013;15(8):701–712. doi: https://doi.org/10.1111/dom.12087

29. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamics variability than insulin glargine under steadystate conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859–864. doi: https://doi.org/10.1111/j.1463-1326.2012.01627.x

30. Heise T, Nørskov M, Nosek L, et al. Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19(7):1032–1039. doi: https://doi.org/10.1111/dom.12938

31. Iga R, Uchino H, Kanazawa K, et al. Glycemic variability in type 1 diabetes compared with degludec and glargine on the morning injection: an open-label randomized controlled trial. Diabetes Ther. 2017;8(4):783–792. doi: https://doi.org/10.1007/s13300-017-0269-0

32. Takahashi H, Nishimura R, Onda Y, et al. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study. Expert Opin Pharmacother. 2017;18(4):335–342. doi: https://doi.org/10.1080/14656566.2017.1293652

33. Henao-Carrilloa DC, Muñoza OM, Gómeza AM, et al. Reduction of glycemic variability with degludec insulin in patients with unstable diabetes. J Clin Transl Endocrinol. 2018;12:8–12. doi: https://doi.org/10.1016/j.jcte.2018.03.003

34. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–732. doi: https://doi.org/10.1056/NEJMoa1615692

35. Danne T, Nimri R, Battelino T, et al. International Consensus on use of continuous glucose monitoring. Diabetes Care. 2017; 40(12):1631–1640. doi: https://doi.org/10.2337/dc17-1600

36. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013;15(3):198–211. doi: https://doi.org/10.1089/dia.2013.0051.

37. Su G, Mi S, Tao H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:19. doi: https://doi.org/10.1186/1475-2840-10-19.